Prenetics Global (NASDAQ:PRE) CFO Acquires 18,000 Shares

Prenetics Global Limited (NASDAQ:PRE) CFO Brian Rosin purchased 18,000 shares of the company’s stock in a transaction that occurred on Monday, August 24th. The shares were purchased at an average cost of $21.19 per share, with a total value of $381,420.00. Following the completion of the acquisition, the chief financial officer owned 18,000 shares in the company, valued at $381,420. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Prenetics Global Price Performance

Shares of NASDAQ PRE opened at $23.25 on Wednesday. The stock’s fifty day moving average price is $19.12 and its two-hundred day moving average price is $18.93. Prenetics Global Limited has a one year low of $7.25 and a one year high of $23.63. The firm has a market cap of $392.23 million, a price-to-earnings ratio of -5.59 and a beta of 0.26.

Prenetics Global (NASDAQ:PRE) last posted its earnings results on Wednesday, August 19th. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.31. Prenetics Global had a negative return on equity of 21.41% and a negative net margin of 47.43%.The company had revenue of $46.49 million during the quarter, compared to the consensus estimate of $49.85 million. On average, equities analysts anticipate that Prenetics Global Limited will post -1.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on PRE. Benchmark lifted their price objective on shares of Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a research report on Friday, July 17th. Finally, Wall Street Zen raised shares of Prenetics Global from a “sell” rating to a “hold” rating in a report on Saturday. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.25.

Institutional Investors Weigh In On Prenetics Global

A number of large investors have recently bought and sold shares of PRE. Jane Street Group LLC bought a new position in Prenetics Global in the 4th quarter valued at about $1,302,000. 683 Capital Management LLC bought a new stake in shares of Prenetics Global during the 4th quarter worth approximately $1,181,000. Millennium Management LLC acquired a new stake in Prenetics Global in the fourth quarter valued at approximately $810,000. Marshall Wace LLP bought a new stake in shares of Prenetics Global during the fourth quarter worth $788,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Prenetics Global during the fourth quarter worth $665,000. 25.01% of the stock is currently owned by institutional investors and hedge funds.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.